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Diabetes and impaired brain insulin signaling are
linked to the pathogenesis of Alzheimer’s disease
(AD). The association between diabetes and AD-
associated amyloid pathology is stronger among
carriers of the apolipoprotein E (APOE) ε4 gene allele,
the strongest genetic risk factor for late-onset AD.
Here we report that apoE4 impairs neuronal insulin
signaling in human apoE-targeted replacement (TR)
mice in an age-dependent manner. High-fat diet
(HFD) accelerates these effects in apoE4-TR mice
at middle age. In primary neurons, apoE4 interacts
with insulin receptor and impairs its trafficking by
trapping it in the endosomes, leading to impaired in-
sulin signaling and insulin-stimulated mitochondrial
respiration and glycolysis. In aging brains, the
increased apoE4 aggregation and compromised en-
dosomal function further exacerbate the inhibitory
effects of apoE4 on insulin signaling and related
functions. Together, our study provides novel mech-
anistic insights into the pathogenic mechanisms of
apoE4 and insulin resistance in AD.
INTRODUCTION
Alzheimer’s disease (AD) is an age-related metabolic neurode-
generative disease (Jack et al., 2010). Diabetes and impaired in-
sulin signaling in the brain are linked to the pathogenesis of AD
(Biessels et al., 2006; Bomfim et al., 2012; Talbot et al., 2012).
Levels of insulin, insulin receptor (IR), and insulin signaling are
lower in AD brains and epidemiological studies have confirmed
that diabetic patients are at higher risk for AD (Craft et al.,
2013; Hoyer, 2004; Steen et al., 2005). Furthermore, peripheral
insulin resistance, a prevalent and increasingly common condi-
tion in developed countries, is associated with significantly lowerregional cerebral glucose metabolism, which in turn predicts
worse memory performance (Willette et al., 2015). Supporting
these, recent phase II clinical trials with insulin nasal spray in
AD patients have yielded positive results in preventing cognitive
decline and this has led to a new national plan for phase II/III trials
(Claxton et al., 2013, 2015). Thus, there is an urgent need to un-
derstand the function and regulation of brain insulin signaling in
preclinical models.
The ε4 allele of the apolipoprotein E (APOE) gene is the stron-
gest genetic risk factor for AD compared to the common ε3 allele
and the protective ε2 allele (Bu, 2009; Liu et al., 2013; Zhao et al.,
2017). Although apoE4 has been shown to impair amyloid-b (Ab)
clearance and promote Ab aggregation leading to enhanced am-
yloid pathology, increasing evidence suggests that apoE iso-
forms differentially regulate brain insulin signaling and glucose
metabolism (Peila et al., 2002; Reiman et al., 1996; Small et al.,
1995). FDG-PET studies showed that APOE4 carriers, either as
healthy adults or with dementia, have lower cerebral glucose
metabolism (Reiman et al., 1996, 2005). Recent clinical trials
have also revealed that the beneficial effects of intranasal insulin
treatment on cognitive improvement in AD patients are modu-
lated byAPOE genotype status (Claxton et al., 2013, 2015; Reger
et al., 2006). The important role of apoE-mediated modulation of
insulin signaling and glucose metabolism is further supported by
our recent observation that conditional deletion of a major apoE
receptor, LRP1, in mouse forebrain neurons leads to impaired
brain insulin signaling and a reduced capacity to metabolize
glucose (Liu et al., 2015). Thus, it is crucial to define the molec-
ular and cellular mechanisms by which apoE isoforms differen-
tially influence brain insulin signaling.
Herein, we show that apoE4-targeted replacement (TR) mice,
in which the endogenous murine Apoe is replaced by human
apoE4, exhibit an impaired insulin signaling and insulin resistance
in the brain in an age-dependent manner. High-fat diet (HFD)-
induced peripheral insulin resistance further exacerbates the
impairment of insulin signaling and insulin response in apoE4-
TRmice.More importantly, we demonstrate that apoE4 interacts
with IRand impairs its trafficking and related signalingby trapping
it in the endosomes. Finally, we found that the increased apoE4Neuron 96, 115–129, September 27, 2017 ª 2017 Elsevier Inc. 115
aggregation and compromised endosomal function exacerbate
the inhibitory effects of apoE4 on insulin signaling and related
functions with aging. Together, our study reveals novel mecha-
nisms by which apoE4 and insulin resistance contribute to AD,
providing biological insights into apoE-targeted therapies to
improve cerebral insulin signaling to treat AD.
RESULTS
Age-Dependent Impairment of Cerebral Basal Insulin
Signaling in ApoE4-TR Mice
Impaired insulin signaling in the central nervous system (CNS)
has been linked to the pathogenesis of AD (Craft and Watson,
2004). Given that the effects on cognition upon intranasal insulin
treatment in adults with dementia are influenced by APOE geno-
type (Reger et al., 2006), we reasoned that insulin signaling in the
brain may be affected by different apoE isoforms. In the canon-
ical insulin signaling pathway, insulin binds to its cognate recep-
tor on the plasma membrane, which induces signal transduction
including phosphorylation of Akt. In turn, activated Akt phos-
phorylates and inhibits GSK3b, which results in dephosphoryla-
tion of GSK3b substrates (Cohen and Frame, 2001). Therefore,
we examined the major downstream molecules involved in insu-
lin signaling in brain homogenates of apoE3- and apoE4-TRmice
at 3, 12, and 22 months of age, representing young, middle,
and old ages, respectively. Intriguingly, we found that the
levels of these key insulin-related signaling molecules includ-
ing phosphorylated-Akt (p-Akt) and phosphorylated-GSK3b
(p-GSK3b) were significantly decreased in both cortex (Figures
1A–1C) and hippocampus (Figures 1D–1F) of apoE4-TR mice
at 22 months of age. However, there were no significant differ-
ences in the amount of p-Akt and p-GSK3b in the cortical frac-
tions of apoE3- and apoE4-TR mice at 3 or 12 months of age
(Figures 1G–1L). To further confirm the specific changes of insu-
lin signaling pathway in these mice, we also examined the levels
of phosphorylated-IR (p-IR), which is the upstream molecule of
p-Akt. Significantly decreased ratio of p-IR to total IR was de-
tected in the cortex of apoE4-TR mice at 22 months of age
compared with apoE3-TR mice (Figure S1A), with no difference
between apoE3-TR and apoE4-TR mice at 3 months of age (Fig-
ure S1B), indicating that basal insulin signaling is impaired in
apoE4-TR mice in an age-dependent manner.
To further examine whether apoE4 affects insulin signaling
pathway in the peripheral tissues of aged apoE4-TR mice, we
examined the levels of p-Akt and p-GSK3b in the skeletal muscle
and liver, two critical sites contributing to peripheral insulin
signaling (DeFronzo and Tripathy, 2009; Michael et al., 2000).
There were no significant differences in the amount of p-Akt
and p-GSK3b in the skeletal muscle (Figures S2A–S2C) and liver
(Figures S2D–S2F) of apoE3-TR and apoE4-TR mice at
22 months of age, indicating that the basal peripheral insulin
signaling remains intact in aged apoE4-TR mice.
High-Fat Diet-Induced Peripheral Insulin Resistance
Accelerates Age-Dependent Impairment of Basal Insulin
Signaling in the Brain of ApoE4-TR Mice
Type 2 diabetes characterized by peripheral insulin resistance,
impaired insulin signaling, and glucose intolerance are associ-116 Neuron 96, 115–129, September 27, 2017ated with cognitive impairment (Ott et al., 1999). To examine
the synergistic interaction between APOE4 and type 2 diabetes
in brain insulin signaling, we investigated whether peripheral
insulin resistance impairs cerebral insulin signaling in an apoE
isoform-dependent manner using a HFD-induced insulin resis-
tance mouse model. The 8-month-old apoE3- and apoE4-TR
mice were fed with HFD (60% fat) or normal-fat (5.8%) diet
(NFD) for 4 months. The fasting glucose levels of HFD-fed mice
(apoE3-TR mice: 171.54 ± 10.08 mg/dL; apoE4-TR mice:
166.71 ± 14.75 mg/dL) were significantly higher than NFD-fed
mice (apoE3-TR mice: 119.25 ± 7.63 mg/dL; apoE4-TR mice:
123.42 ± 8.08 mg/dL) supporting a peripheral insulin-resistance
phenotype after HFD treatment (Winzell and Ahrén, 2004).
Intriguingly, apoE4-TR mice fed with HFD exhibited a significant
decrease in the activation of downstream insulin signaling, indi-
cated by the reduced ratios of p-Akt/Akt and p-GSK3b/GSK3b in
the cortex (Figure 2A) and hippocampus (Figure 2B) compared
with HFD-fed apoE3-TR mice at 12 months of age. These
apoE isoform-dependent effects were not observed in mice
fed with NFD. These results demonstrate that HFD-induced pe-
ripheral insulin resistance and apoE4 synergistically reduce ce-
rebral insulin signaling.
ApoE4 Reduces Tissue Sensitivity to Insulin Stimulation
Cerebral insulin resistance, indicated by reduced cellular
responsiveness to insulin, is a common pathological feature of
AD (Sims-Robinson et al., 2010; Talbot et al., 2012). We thus
sought to investigate whether apoE4 affects the insulin sensi-
tivity in the brain. Insulin was delivered to the left hippocampus
of aged apoE-TRmice or HFD-treated apoE-TRmice via reverse
microdialysis and insulin signaling was evaluated in both ipsilat-
eral and contralateral sides of insulin delivery. We found that the
increase of insulin-induced signaling in the hippocampus was
significantly lower in apoE4-TR mice compared with apoE3-TR
mice both under aged condition (Figure 3A) and HFD treatment
(Figure 3B), suggesting that aged apoE4-TR mice develop cere-
bral insulin resistance that can be further accelerated by HFD-
induced peripheral insulin resistance conditions.
IR has been shown to be more concentrated in neurons rela-
tive to glial cells in the brain and its distribution is particularly
high in post-synaptic density (Unger et al., 1991), suggesting a
critical role of insulin signaling in neurons. Thus, we first tested
how apoE isoforms affect the response of insulin in neurons.
Apoe/ primary neurons were treated with recombinant
apoE3 or apoE4, followed by insulin stimulation. Similar to the
in vivo results, apoE4 treatment led to reduced insulin signaling
in primary neurons (Figure 3C), suggesting that apoE4 sup-
presses the action of insulin in neurons.
To examine the effects of apoE on the peripheral insulin-stim-
ulated responses, we detected the activation of insulin signaling
in the skeletal muscle of aged apoE-TR mice after injection of in-
sulin into inferior vena cava. We found that the increase of insulin
signaling in the skeletal muscle was significantly lower in aged
apoE4-TR mice compared with that in apoE3-TR mice (Fig-
ure S3A). ApoE4 also inhibited the activation of insulin signaling
in HuH7 hepatoma cells (Figure S3B). These results suggest that
apoE4 may reduce the peripheral insulin sensitivity upon insulin
stimulation.
Figure 1. ApoE4 Impairs Cerebral Basal Insulin Signaling in an Age-Dependent Manner
(A–L) Brain lysates from apoE3-TR and apoE4-TR mice (n = 4–6 mice/genotype, mixed gender) at 22 months (A–F), 12 months (G–I), and 3 months (J–L) of age
were prepared and the amount of p-Akt (Ser473), total Akt, p-GSK3b (Ser9), and total GSK3b in the cortex (A–C, G–L) and hippocampus (D–F) was examined by
western blotting. Results were normalized to b-actin levels. The ratios of p-Akt/total Akt and p-GSK3b/total GSK3b were quantified and calculated. Data are
expressed as mean ± SEM relative to apoE3-TR mice. Two-tailed Student’s t test was used for statistical analysis. *p < 0.05; **p < 0.01; N.S., not significant.
Molecular mass markers in kilodaltons are shown. See also Figures S1 and S2.ApoE4 Inhibits Insulin-Induced Effects onMitochondrial
Respiration and Glycolysis in Primary Neurons
Recent evidence indicates that insulin resistance and mitochon-
drial dysfunction are common pathological features connecting
type 2 diabetes to AD (De Felice and Ferreira, 2014). It has
been reported that insulin could regulate both mitochondrial
respiration and glycolysis, the two major pathways of energy
metabolism (Beitner and Kalant, 1971; Garcı́a-Cáceres et al.,
2016; Nisr and Affourtit, 2014). To further investigate how
apoE4 alters the function of insulin signaling on energy meta-
bolism, we evaluated intracellular mitochondrial respiration andglycolysis simultaneously by Seahorse XF96 Extracellular Flux
analyzer, a sensitive, high-throughput instrument (Zhang et al.,
2012). Using this technology, we were able to quantitatively
compare intracellular glucose-mediated energy metabolism in
neurons treated with different apoE isoforms. The Apoe/ neu-
rons were treated with vehicle or recombinant apoE3 or apoE4
protein overnight in insulin-free media followed by 30 min insulin
treatment. To testmitochondrial respiration, we created bioener-
getic profiles in which changes in oxygen consumption rate
(OCR) were assessed over time after sequential injections of
different inhibitory compounds for the critical enzymes in theNeuron 96, 115–129, September 27, 2017 117
Figure 2. HFD Treatment Accelerates the Age-Dependent Impairment of Cerebral Basal Insulin Signaling in ApoE4-TR Mice
ApoE3-TR and apoE4-TR mice (n = 8–9 mice/genotype/treatment group, mixed gender) at middle age (8 months) were fed with either NFD or HFD for 4 months.
The amount of p-Akt (Ser473), total Akt, p-GSK3b (Ser9), and total GSK3b in the cortex (A) or hippocampus (B) was examined by western blotting. The ratios of
p-Akt/total Akt and p-GSK3b/total GSK3b were calculated. Data were normalized to apoE3-TR mice for comparison. Two-tailed Student’s t test was used for
statistical analysis within the group. *p < 0.05; N.S., not significant. Molecular mass markers in kilodaltons are shown.electron transport chain of the mitochondria (Figures 4A–4C).
Based on these profiles, basal respiration and maximal respira-
tion were calculated. To measure glycolysis, we assessed
the extracellular acidification rate (ECAR), produced indirectly
following glucose to lactate conversion independent of oxygen,
over time and these profiles were used to calculate glycolysis
rate and glycolytic capacity (Figures 4D–4F). We observed that
insulin significantly increased basal and maximal mitochondrial
respiration (Figure 4A), glycolysis rate, and glycolytic capacity
(Figure 4D) in Apoe/ neurons. ApoE3 treatment neither
affected insulin-induced mitochondrial respiration (Figure 4B)
nor glycolysis (Figure 4E). Interestingly, apoE4 treatment signifi-
cantly inhibited insulin’s ability to increase neuronal mitochon-
drial respiration (Figure 4C) and glycolysis (Figure 4F).
To further confirm these results, we treated Apoe/ neurons
with astrocyte-secreted apoE3 or apoE4 lipoprotein particles
that are lipidated and more closely mimic the biochemical prop-
erties of apoE in vivo. Similarly, lipidated apoE4, but not apoE3,
particles inhibited insulin-induced effects on mitochondrial
respiration and glycolysis (Figures S4A–S4F). These results indi-
cate that apoE4, but not apoE3, suppresses insulin-stimulated
mitochondrial respiration and glycolysis in neurons.
ApoE4 Interacts with Insulin Receptor and Impairs Its
Trafficking
Internalization of IR has been shown to play a critical role in the
signaling events (Di Guglielmo et al., 1998; Kublaoui et al.,
1995). Insulin signaling is initiated through the binding of insulin118 Neuron 96, 115–129, September 27, 2017to the cell surface IR, a disulfide-linked heterotetramer consist-
ing of two homologous a and b subunits. Upon insulin binding
to the extracellular a subunit of IR, a conformational change of
IR leads to b subunit autophosphorylation, which triggers the
rapid endocytosis of the insulin-IR complex with concomitant
downstream signaling activation (Carpentier et al., 1978; Gorden
et al., 1978). Once IR is sequestered from insulin in the endoso-
mal compartment, the majority of receptor is recycled back to
the plasma membrane, presumably for another round of ligand
binding and internalization, while a small amount of the receptor
is destined to lysosome for degradation (Baldwin et al., 1980; Tri-
schitta et al., 1989). Thus, to investigate how apoE4 impairs insu-
lin signaling, we first investigated whether apoE4 could disrupt
insulin and IR interaction by binding to either insulin or IR. Using
a solid-phase binding assay in which recombinant insulin or IR
was incubated with immobilized apoE3 or apoE4, we did not
detect a specific binding between apoE and insulin (data not
shown). Conversely, we found that both recombinant apoE3
and apoE4 specifically bound to IR with apoE4 having higher
binding affinity than apoE3 (Figure 5A). Furthermore, we exam-
ined the interaction of IR with lipidated apoE purified from the
conditioned medium of astrocytes, a physiologically more rele-
vant source of brain apoE. Importantly, the binding affinities of
astrocyte-secreted apoE3 and apoE4 lipoprotein particles for
IR were 10 times higher than their corresponding recombinant
apoE (Figure 5B). Similar to recombinant apoE, we found
that apoE4 lipoprotein particles bind to IR more strongly than
apoE3 lipoprotein particles (Figure 5B). No specific binding
Figure 3. ApoE4 Reduces Insulin-Induced Sensitivity to Insulin
Signaling
(A and B) The amount of hippocampal p-Akt (Ser473), total Akt, and b-actin in
old (22 months) apoE-TR mice (A) or HFD-treated middle-age (12 months)
apoE-TR mice (B) was examined by western blotting after insulin treatment via
reverse microdialysis (n = 4 mice/genotype, male). Results were normalized to
b-actin levels. Both contralateral (without insulin) and ipsilateral (with insulin)
hippocampal homogenates from the same animal were analyzed on the same
blot and the change in p-Akt/total Akt ratio in response to insulin treatment was
calculated. Data were normalized to apoE3-TR mice for comparison.
(C) Apoe/ primary neurons were treated overnight with 50 nM recombinant
apoE3 or apoE4 followed by insulin treatment (100 nM) for 30 min. The amount
of p-Akt (Ser473), total Akt, and b-actin was detected by western blotting
(three independent experiments). The change in p-Akt/total Akt ratio after in-
sulin treatment was calculated.
Data were normalized to apoE3 treatment for comparison. Values are ex-
pressed as mean ± SEM. Two-tailed Student’s t test was used for statistical
analysis. *p < 0.05. Molecular mass markers in kilodaltons are shown. See also
Figure S3.was detected between IR and apolipoprotein J (apoJ, also
known as clusterin) (Figure S5), another important lipoprotein
in the brain that has been implicated in AD pathogenesis (Caleroet al., 2000). These findings support the binding specificity be-
tween apoE and IR. In addition, we further verified the binding
of apoE to IR using a solution binding assay followed by co-
immunoprecipitation. Recombinant apoE and IR were co-incu-
bated for 1 hr at 37C, and the apoE was pulled down by an
apoE-specific antibody. We found that more IR was co-immuno-
precipitated with apoE4 than with apoE3 (Figure 5C). To further
identify the interacting domain of apoE, we performed solid-
phase binding assays to assess the binding of IR with full-length
(FL) apoE (aa1–299) or C-terminal truncated apoE (aa1–186)
(Figures 5D and 5E). Interestingly, the binding ability of truncated
apoE to IR was significantly decreased, with 50% reduction in
truncated apoE3 (Figure 5D) and 30% reduction in truncated
apoE4 (Figure 5E) compared to the FL apoE, indicating the
involvement of C-terminal domain of apoE in IR binding. Taken
together, these data demonstrated that apoE binds to IR in an
isoform-dependent manner with apoE4 showing higher binding
affinity than apoE3.
To further confirm the interaction between apoE and IR in vivo,
we immunoprecipitated apoE from the brain lysates of young
(3 month) or old (22 month) apoE-TR mice. Interestingly, IR
was co-immunoprecipitated with apoE in old apoE4-TR mice
but not in apoE3-TR mice or in young apoE4-TR mice under
these experimental conditions (Figure S6A). We also performed
the assay in a reciprocal fashion in which apoE was co-immuno-
precipitated with IR exclusively in 22-month-old apoE4-TR mice
(Figure S6B), suggesting an increased binding between apoE4
and IR with aging.
To examine whether apoE4 interferes with the interaction be-
tween insulin and IR, we determined the kinetics of insulin-IR
binding using solid-phase binding assay. Based on this binding
kinetics, we chose appropriate insulin and IR concentrations
for the apoE competition experiments. When apoE was co-incu-
bated with insulin and IR, we found that apoE4 (16 mg/mL)
reduced insulin-IR binding by nearly 50%, which is significantly
higher than apoE3 treatment (25%) (Figure 5F). These results
indicate that apoE interferes with insulin-IR interaction in an iso-
form-dependent manner with apoE4 exhibiting greater detri-
mental effects.
Since insulin binding to IR triggers its translocation from the
plasma membrane to the endosomal compartment, an event
that is important for the full activation of signaling cascade (Di
Guglielmo et al., 1998; Kublaoui et al., 1995), we next investi-
gated whether apoE isoforms differentially affect IR internaliza-
tion. Apoe/ neurons were treated with different apoE isoforms
and the amount of cell surface IR was evaluated by cell surface
biotinylation assay. In the absence of insulin stimulation, we
found that apoE4 but not apoE3 significantly reduced the
amount of cell surface IR (Figures 5G and 5H). Importantly,
50% of the total IR was internalized in response to insulin in
apoE3-treated cells, whereas only 20% of IR was internalized
in apoE4-treated cells upon insulin stimulation (Figure 5I). These
results were consistent with our observations that apoE4 sup-
pressed the activation of insulin signaling compared to apoE3
(Figures 5G, 5J, 5K, and 3C), likely by blocking the insulin-IR
interaction and thus suppressing IR internalization and signaling
activation. Moreover, as apoE4 downregulates cell surface IR
even in the absence of insulin, it is possible that in the presenceNeuron 96, 115–129, September 27, 2017 119
Figure 4. ApoE4 Inhibits Insulin-Induced Mitochondrial Respiration and Glycolysis
Mitochondrial respiration and glycolysis were measured by Seahorse XFe96 analyzer in Apoe/ neurons treated overnight with vehicle or 50 nM recombinant
apoE3 or apoE4 followed by insulin (100 nM) treatment for 30 min.
(A–C) Oxygen consumption rate (OCR) was assessed over time after sequential injections of 2 mM oligomycin, 1 mM FCCP, and 5 mM rotenone/antimycin A. The
basal respiration and the maximal respiration were calculated to compare the effect of insulin treatment.
(D–F) The extracellular acidification rate (ECAR) was assessed over time after sequential injections of glucose (10 mM), oligomycin (2 mM), and 2-DG (50mM). The
glycolysis rate and glycolytic capacity were calculated to compare the effect of insulin treatment.
Each value was derived from 10 to 12 repeats in two independent experiments and normalized to the third data point measurement of baseline from non-insulin
treatment group for comparisons. Data are expressed as mean ± SEM. Two-tailed Student’s t test was used for statistical analysis. ****p < 0.0001; N.S., not
significant. Oligo, Oligomycin; FCCP, Carbonyl cyanide-p-trifluoromethoxyphenylhydrazone; RA, rotenone/antimycin A. See also Figure S4.of apoE4 less amount of IR is available on the surface for the ac-
tion of insulin.
A previous study reported that the recycling of apoE4 is
impaired in primary neurons in which more apoE4 is retained120 Neuron 96, 115–129, September 27, 2017within intracellular compartments compared with apoE3 (Chen
et al., 2010). Thus, we hypothesized that decreased cell surface
IR following apoE4 treatment resulted from an impairment of
apoE4-related trafficking. To test this, we expressed human IR
Figure 5. ApoE4 Suppresses the Amount of Cell Surface IR
(A and B) The interaction between IR and recombinant apoE (A) or astrocyte-secreted lipidated apoE particles (B) were evaluated by solid-phase binding assay
(three independent experiments). The dissociation constant (Kd) values of the binding curves were calculated using the one-site specific binding equation.
(C) The interaction between IR and recombinant apoEwas evaluated by solution binding assay, followed by immunoprecipitation (IP) of apoE and immunoblotting
(IB) of IR. The ratio of IR to apoE was calculated. The values were normalized to apoE3 for comparison.
(D and E) The domain interaction between apoE and IRwas determined by solid-phase binding assay (three independent experiments) using C-terminal truncated
apoE3 or apoE4 containing the aminol acid (aa) 1–186 compared with the full-length (FL) of apoE. The values were normalized to the binding of apoE FL for
comparison.
(F) A competitive inhibition assay of insulin (8 nM), IR (80 nM), and apoE (4, 8, or 16 mg/mL) was analyzed using solid-phase binding assay (three independent
experiments). Results were normalized to the maximal binding of insulin and IR in the absence of apoE.
(G–K) Primary Apoe/ neurons were treated overnight with recombinant apoE3 or apoE4 (100 nM) in the presence or absence of insulin (100 nM) stimulation for
30min, followed by cell surface biotinylation assay andwestern blot analysis (three independent experiments). The cell surface IR and total IR were shown and the
ratio of cell surface IR/total IRwas calculated (G andH). The values were normalized to the vehicle-treated group (V) for comparison. The change in cell surface IR/
total IR after insulin treatment was evaluated (I). The amount of p-Akt (Ser473), total Akt, and b-actin was detected by western blotting (G, J, and K). Ratio of p-Akt
to total Akt (J) and insulin-induced p-Akt/Akt change (K) were calculated. The values were normalized to vehicle without insulin treatment group for comparison.
All data represent mean ± SEM. Two-tailed Student’s t test (A–C, F, I, and K) and one-way ANOVA with Tukey’s multiple comparisons test (D, E, H, and J) were
used in for statistical analysis. *p < 0.05; **p < 0.01; N.S., not significant. Molecular mass markers in kilodaltons are shown. See also Figures S5–S9.
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tagged with GFP in SH-SY5Y neuronal cells and tracked IR-GFP
localization following treatment with apoE isoforms in the
presence or absence of insulin stimulation. In the absence of in-
sulin, the majority of the IR-GFP was localized to the cell mem-
brane with only 15% of the receptor localized intracellularly in
apoE3-treated cells (Figures 6A–6C). Interestingly, nearly 40%
of IR-GFP was localized in the intracellular compartment in
apoE4-treated cells (Figures 6A–6C), consistent with our obser-
vation in which apoE4 reduced cell surface IR (Figures 5G–5I).
Importantly, insulin stimulation increased the percentage of
intracellular IR-GFP in apoE3-treated, but not in apoE4-treated,
cells (Figures 6A–6C).
To investigate the intracellular trafficking and distribution of IR
after incubation with apoE and/or insulin, IR-GFP-expressing
cells were labeled with Alexa Flour 568-conjugated transferrin
(Tf), a marker of the early endosome and recycling endosome.
In the absence of insulin, we found that nearly 20% of IR-GFP
co-localized with transferrin in the endosomal compartment in
apoE4-treated cells, whereas less co-localization was observed
in apoE3-treated cells (Figures 6A and 6D). Insulin induced IR
internalization, which increased the co-localization of IR-GFP
with transferrin in apoE3-treated cells, but not in apoE4-treated
cells (Figures 6A and 6D). No differences were observed for
the co-localization of IR-GFP with Lysotracker, a lysosomal
marker, between apoE3- and apoE4-treated cells, with or
without insulin (Figures 6B and 6E). These results suggest that
the slower recycling of apoE4 might trap IR in the endosomal
compartment, thereby impairing its ability to bind insulin and
trigger IR signaling at the cell surface.
We next investigated whether apoE4 affects the trafficking of
other membrane receptors in neurons, including the low-density
lipoprotein receptor-relatedprotein 1 (LRP1),N-methyl-D- aspar-
tate receptor (NMDAR), anda-amino-3-hydroxy-5-methyl-4- iso-
xazolepropionic acid receptor (AMPAR), as well as a plasma
membranemarker Na-K-ATPase. Apoe/ neurons were treated
with different apoE isoforms and the amount of cell surface IR,
LRP1, NMDAR, AMPAR, and Na-K-ATPase were evaluated by
cell surface biotinylation assay. As expected, cell surface IR
was decreased after treatment with apoE4 compared with
apoE3 (Figures S7A and S7B) without affecting the total IR (Fig-
ures S7A and S7G). No significant differences were found in the
levels of cell surface and total LRP1, NMDAR, AMPAR, and
Na-K-ATPase after apoE3 and apoE4 treatments (Figures S7A,
S7C–S7F, and S7H–S7K). These results indicate that apoE4 spe-
cifically suppresses cell surface IR in neurons.
To directly test how apoE isoforms differentially affect IR traf-
ficking, we evaluated the internalization and recycling of IR using
cell surface biotinylation techniques in cultured Apoe/ cortical
neurons. The internalization of IR reached plateau at 30 min after
treatment with either apoE3 or apoE4 (Figure S8A). After 60 min
treatment with apoE3, the amount of internalized (biotinylated) IR
was reduced, reflecting a membrane recycling of IR and subse-
quent biotin cleavage. Interestingly, apoE4-treated cells ex-
hibited significantly more intracellular IR compared to those
treated with apoE3 at 60 min, suggesting a delayed recycling
of IR in the presence of apoE4 (Figure S8A). A recycling assay
was then performed to further confirm this finding. Cells were
treated with apoE3 or apoE4 for 30 min to allow the maximal122 Neuron 96, 115–129, September 27, 2017internalization of biotinylated IR. After removal of apoE, the bio-
tinylated IR that recycled back to cell surface was removed by
glutathione cleavage. Thus, the reduction of intracellular (bio-
tinylated) IR over time represents the recycling of this receptor.
Intriguingly, significantly higher amount of intracellular IR was
detected in apoE4-treated cells compared with cells treated
with apoE3 at 30 min and 60 min, indicating that apoE4 impaired
IR recycling (Figure S8B). To further test how apoE isoforms
differentially affect insulin-induced IR trafficking, we monitored
IR internalization after insulin treatment in the absence or pres-
ence of apoE. Insulin-induced rapid endocytosis of IR with the
plateau appeared at 5 min and then steadily declined, reflecting
membrane recycling of IR and subsequent biotin cleavage (Fig-
ure S9). In the presence of apoE3, the plateau of the curve shifted
to 15 min and then started to decline (Figure S9). However, in the
presence of apoE4, the internalization of IR did not approach
plateau until 30 min and without obvious decline over time
(Figure S9), indicating that apoE4 inhibits insulin-induced IR
trafficking.
ApoE4 Accelerates the Aggregation of IR with Aging
Aggregation of certain cellular proteins is a common feature of
aging in particular under aging-related neurodegenerative condi-
tions (David et al., 2010; Lindner and Demarez, 2009). We spec-
ulate that apoE4 may be prone to aggregation during aging,
which can in turn impair the functions of IR and insulin signaling
in an age-dependentmanner. To examine the aggregation status
of apoE isoforms and IR in the brains, we sequentially extracted
the cortex of young (3 months of age) and aged (22 months of
age) apoE-TR mice with RIPA buffer (detergent-soluble fraction)
and guanidine (GND, detergent-insoluble fraction). The levels of
soluble apoE and IR in RIPA fractions were detected by western
blotting and ELISA; the insoluble apoE and IR in GND fractions,
which contain the aggregated proteins, were detected by ELISA.
The amounts of soluble apoE did not significantly differ between
young and old mice regardless of APOE genotypes (Figures 7A,
7B, and 7D). Intriguingly, the level of insoluble apoE was signifi-
cantly increased in aged apoE4-TR mice compared with that in
young mice (Figure 7E), leading to an increased insoluble-to-sol-
uble ratio of apoE with aging (Figure 7F). To a lesser extent, there
was a trend of an increased insoluble-to-soluble apoE ratio with
aging in apoE3-TR mice (Figures 7E and 7F). The increase of
insoluble apoE4 in aged brain suggests that apoE4 might be
more prone to aggregationwith aging compared to apoE3.More-
over, the level of detergent-soluble IRwassignificantly decreased
with aging in apoE4-TR mice, but not in apoE3-TR mice (Figures
7A and 7G). Though the insoluble IR was increased in aged mice
with either APOE genotype (Figure 7H), the ratio of insoluble-to-
soluble IR was found to be significantly increased only in aged
apoE4-TRmice (Figure 7I). Taken together, these results suggest
that apoE4might bemore likely to aggregate during aging, which
accelerates IR aggregation and impaired functions.
ApoE4 Induces Early Endosomal Abnormality with Aging
Endocytosis is crucial to variouscellular functions, including inter-
cellular communication, signal transduction, and metabolism;
thus, even subtle abnormality in the endocytic compartments of
cells in the brain may have a substantial impact on neuronal
Figure 6. ApoE4 Impairs IR Trafficking by Trapping IR in the Endosome
SH-SY5Y neuronal cells transfected with human IR-GFP were treated overnight with recombinant apoE3 or apoE4 (100 nM) in the presence or absence insulin
(100 nM) stimulation for 30 min. Alexa Flour 568-labeled human transferrin (Tf, 20 mg/mL) or Lysotracker (10 mM) was added to the medium 1 hr before fixing the
cells and images were obtained by confocal microscopy.
(A) The co-localization of IR-GFP (green) and Tf (red) in apoE3- and apoE4-treated cells in the presence and absence of insulin is shown. DAPI (blue) was included
to position the nucleus.
(B) The co-localization of IR-GFP (green) and Lysotracker (red) in apoE3- and apoE4-treated cells in the presence and absence of insulin is shown. DAPI (blue) was
included to position the nucleus.
(C) Percentage of intracellular IR (intra-IR/total IR) was calculated.
(D) Percentage of IR that was co-localized with Tf (Tf co-localized IR) was calculated.
(E) Percentage of IR that was co-localized with Lysotracker (Lysotracker co-localized IR) was calculated.
Data from three independent experiments are expressed asmean ± SEM. Two-tailed Student’s t test was used for statistical analysis. ***p < 0.001; ****p < 0.0001;
N.S., not significant. Scale bar, 20 mm. See also Figures S8 and S9.
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Figure 7. ApoE4 Aggregation in Aging Brain Accelerates the Insolubility of IR
(A–I) RIPA and guanidine (GND)-extracted brain cortical lysates of apoE3-TR and apoE4-TR mice (n = 4–6 mice/genotype, mixed gender) at 3 and 22 months of
age were prepared and the amount of apoE and IR was examined by western blotting (A–C) and ELISA (D–I). Results were normalized to b-actin levels in western
blot analysis. The ratios of insoluble (GND fraction) to soluble (RIPA fraction) apoE (F) and IR (I) were calculated. Data are expressed as mean ± SEM. Two-way
ANOVA with Tukey’s multiple comparisons test was used for statistical analysis. **p < 0.01; ***p < 0.001; N.S., not significant. Molecular mass markers in
kilodaltons are shown.functions (Nixon, 2005). The enlargement of Rab5-positive endo-
somes has been shown to occur early and precede the onset of
axonal dysfunction and AD pathogenesis (Ginsberg et al., 2010;
Grbovic et al., 2003; Xu et al., 2016). Furthermore, it was shown
that the presence of APOE4 accentuates Rab5-positive endoso-
mal enlargement at preclinical stages of AD (Cataldo et al., 2000).
To test how apoE isoforms differently affect endocytic system
with aging, we performed Rab5 staining with brain slices from
apoE-TRmice at 3 months or 22 months of age. There was a sig-
nificant upregulation of Rab5 immunoreactivity in the cortex and
amygdala regions of apoE4-TR mice at 22 months of age
compared with that of apoE3-TR mice (Figures 8A–8C), whereas
no difference was found among 3-month-old apoE-TR mice
(Figures S10A–S10C), suggesting an age-related endocytic
dysfunction in apoE4-TR mice. Thus, the compromised endoso-
mal functionmay exacerbate the inhibitory effects of apoE4on in-
sulin signaling and related functions with aging.124 Neuron 96, 115–129, September 27, 2017DISCUSSION
Impaired insulin signaling has been demonstrated in both post-
mortem human AD brains and in mouse models of AD (Hoyer,
2004; Steen et al., 2005). Interestingly, in clinical trials the bene-
ficial role of intranasal insulin delivery on improving cognition in
AD patients is modulated by APOE genotype status (Claxton
et al., 2013, 2015; Reger et al., 2006). In this study, we found
that apoE4 impairs cerebral insulin signaling in an age-depen-
dent manner in vivo, consistent with a previous report (Ong
et al., 2014). Additionally, HFD-induced peripheral insulin resis-
tance and apoE4 synergistically impair cerebral insulin signaling.
By delivering insulin into the mouse brain via the in vivo reverse
microdialysis approach, or by administrating insulin into periph-
eral organ through the inferior vena cava injection, we found that
apoE4 reduces both the cerebral and peripheral responsiveness
of insulin-induced signaling. Most importantly, we demonstrated
Figure 8. Aged ApoE4-TR Mice Exhibit Elevated Early Endosomal
Marker
(A) Brain slices from apoE3-TR and apoE4-TR mice at 22 months of age were
prepared, and the early endosomes were examined by immunohistochemical
staining for Rab5. The Rab5 expression pattern in the cortex and amygdala is
shown (A). Scale bar, 100 mm.
(B and C) The immunoreactivity of Rab5 staining in the cortex and amygdala
from apoE3-TR and apoE4-TR mice was quantified using Aperio ImageScope
(n = 6 mice/genotype, mixed gender).
Data are expressed as mean ± SEM relative to apoE3-TR mice. Two-tailed
Student’s t test was used for statistical analysis. *p < 0.05. See also Figure S10.that apoE4 impairs neuronal insulin signaling by binding to IR and
trapping IR in the endosomes. Furthermore, we found that apoE4
accelerates IR aggregation and is associated with endocytic ab-
normality with aging. Our findings provide new insights into the
molecular mechanisms responsible for the apoE isoform effects
on cerebral insulin signaling, providing mechanistic insights for
insulin-based AD prevention and therapy.
The action of insulin is initiated through binding to cell surface
IR followed by internalization of the insulin-IR complex. Here, we
demonstrated that apoE4 interacts with IR to block insulin bind-
ing to its cognate receptor (Figure S11). Using multiple ap-
proaches, we found that apoE4 binds to IR with higher affinity
compared with apoE3; thus, apoE4 may block insulin-IR binding
more efficiently. ApoE4 has been suggested to self-aggregate
more easily than other apoE isoforms (Hatters et al., 2006),
although there are some discrepancies regarding the dimeriza-
tion of apoE (Aleshkov et al., 1997; Elliott et al., 2010; Martelet al., 1997; Weisgraber and Shinto, 1991). It is also possible
that the aggregated apoE4 physically interferes with the interac-
tion between IR and insulin. Consequently, apoE4 abrogates the
action of insulin to induce IR internalization, which is critical
for the maximal activation of insulin signaling. Furthermore,
apoE4 exhibits a greater propensity to accumulate intracellularly
following internalization due to impaired recycling (Heeren et al.,
2004). The acidic environment in the early endosomal compart-
ment has been proposed to enhance apoE4 self-aggregation
(Morrow et al., 2002), which may further sequester interacting
proteins including insulin receptor. Our current study showed
that apoE4 suppresses cell surface IR by impairing IR trafficking,
whereby more IR is retained in the early endosome together with
apoE4. As a result, the downstream signaling and the effects of
insulin-induced glycolysis and mitochondrial respiration are
significantly suppressed by apoE4 (Figure S11). With aging, the
increased apoE4 aggregation and compromised endosomal
function exacerbate the inhibitory effects of apoE4 on insulin
signaling and related functions (Figure S11). Chen and col-
leagues reported that apoE4 reduces surface level of Apoer2,
a neuronal signaling receptor for Reelin and apoE, as well as
glutamate receptors by sequestration of them in intracellular
compartments, thereby reducing synaptic activity (Chen et al.,
2010; Lane-Donovan et al., 2014). These studies, including
ours, suggest that apoE4 may suppress various signaling cas-
cades by impairing the trafficking of cell surface receptors. The
accumulation of proteins in the intracellular compartments might
contribute to endocytic dysfunction during aging, which may
further exacerbate the inhibitory effects of apoE4.
Since amyloid-b (Ab) impairs insulin signaling both in vivo and
in vitro (Craft et al., 2000, 2013; Craft and Watson, 2004; Hoyer,
2004; Steen et al., 2005), it will be important to examine whether
Ab further exacerbates apoE4-mediated deleterious effects on
insulin signaling. It was reported that the disturbance of insulin
signaling was worse in amyloid model mice expressing human
apoE4 (ApoE4/APP), which correlates with poorer memory per-
formance, compared with ApoE3/APP mice (Chan et al., 2015,
2016). However, it is still unclear whether Ab and apoE4 play syn-
ergistic or competing roles in disrupting insulin signaling. It was
shown that in the presence of Ab, apoE4 bound more to Ab
whereas apoE3 boundmore to IR (Chan et al., 2015). Our current
findings demonstrate that apoE4 has higher binding affinity to IR
in the absence of Ab. Whether Ab alters the binding status be-
tween IR and apoE isoforms requires further investigation.
Furthermore, it was reported that IR is involved in the Ab clear-
ance, thus the dysfunction of IR impairs the intracellular clear-
ance of oligomeric Ab in primary cultured neurons (Zhao et al.,
2009). It will be interesting to test how apoE isoforms affect IR-
regulated Ab clearance.
Additionally, APOE genotype status appears to modulate
cognitive responses to insulin and insulin-based AD therapies
in several clinical trials. For example, AD patients who are
APOE4 non-carriers show memory facilitation after insulin infu-
sion, whereas APOE4 carriers are cognitively unaffected in
response to insulin (Craft et al., 2000). Acute administration of
short-acting intranasal insulin improves cognition in AD patients
who are APOE4 non-carriers, whereas no improvement is found
in APOE4 carriers treated with any of the doses (Reger et al.,Neuron 96, 115–129, September 27, 2017 125
2008). Interestingly, the long-acting intranasal insulin modulates
cognition in AD patients with improvement for APOE4 carriers
and worsening for non-carriers (Claxton et al., 2015). Our results
that apoE4 impairs cerebral insulin signaling and induces insulin
resistance might explain why acute intranasal insulin stimulation
benefits APOE4 non-carriers but not carriers. However, chronic
insulin treatment might induce cerebral insulin resistance in
APOE4 non-carriers who have normal insulin response. It is
possible that APOE4 carriers who already exhibit insulin resis-
tance in the brain may require moderate but long-lasting stimu-
lation; thus, long-lasting insulin exposure might be beneficial.
Future studies will be needed to further understand the mecha-
nistic basis of APOE isoform-related differences upon insulin
treatments in order to design individualized therapies for AD
based on APOE genotype status.
Peripheral insulin resistance and dyslipidemia, the defining
features of type 2 diabetes, exacerbate Ab pathology and in-
crease tau phosphorylation in AD patients (Ho et al., 2004; Kim
et al., 2009a). Increasing evidence suggests that the presence
of APOE4 allele and type 2 diabetes synergistically affect AD
pathogenesis. For example, individuals with both diabetes and
APOE4 have the highest risk for AD and exhibit the most severe
neuropathology (Peila et al., 2002). In our study, HFD-induced
peripheral insulin resistance led to accelerated insulin signaling
defects from old tomiddle ages, suggesting that peripheral insu-
lin resistance is a critical factor that accelerates apoE4-induced
impairment of cerebral insulin signaling. Previous studies
showed that insulin resistance promotes vascular dysfunction
and dyslipidemia, which further exacerbate glucose and lipid ab-
normalities (Craft, 2009), resulting in a vicious cycle between
progressive vascular dysfunction and enhanced insulin resis-
tance. Thus, it is possible that apoE4 exacerbates insulin resis-
tance by modulating lipid metabolism and vascular functions in
the brain. Further understanding on the molecular mechanisms
by which apoE4 and peripheral insulin resistance synergistically
increase the risk of AD will help develop therapeutic strategy to
treat this disease.
According to previous clinical findings, apoE4 status is not
associated with the risk of type 2 diabetes (Anthopoulos et al.,
2010). In our study, we detected a decreased signaling activation
in the skeletal muscle of aged apoE4-TR mice upon acute pe-
ripheral stimulation of high-dose insulin, whereas the basal
signaling in both skeletal muscle and liver at the steady state
did not significantly differ between aged apoE3- and apoE4-TR
mice. These results suggest that the peripheral system may
possess a certain compensation mechanism that allows the
basal insulin signaling to be maintained under the physiological
condition. In addition, peripheral and cerebral apoE may have
different functions (Zhao et al., 2017). ApoE is mainly produced
by hepatocytes and macrophages in the peripheral tissues,
whereas in the CNS, apoE is highly expressed by astrocytes
(Xu et al., 2006). The blood-brain barrier limits the transport of
apoE into and out of the brain such that peripheral and cerebral
apoE molecules are in separate pools (Lane-Donovan et al.,
2016). The plasma apoE is desialylated and preferentially asso-
ciated with very low-density lipoprotein particles, whereas the
apoE in the CNS is found in high-density lipoprotein (HDL)-like
particles (Kim et al., 2009b). These observations suggest that pe-126 Neuron 96, 115–129, September 27, 2017ripheral and brain apoE proteins exhibit distinct lipidation status,
post-translational modifications, and functions, which may
contribute to the differential effects of apoE isoforms on the
regulation of insulin signaling in the periphery and CNS. Future
studies are required to investigate the different regulatory path-
ways of insulin signaling in the CNS and periphery.
We previously revealed that LRP1 interacts with IR in the brain
and regulates insulin signaling (Liu et al., 2015). LRP1 could also
regulate hepatic insulin response (Ding et al., 2016). As LRP1 is a
major apoE receptor, we examined whether apoE4 affects the
trafficking of LRP1.We found that apoE4 suppresses cell surface
IR, but has no effect on cell surface LRP1 levels. In addition, our
in vitro and in vivo results showed that apoE4 is capable of bind-
ing to IR, and such interaction becomes more pronounced in
aged apoE4-TRmice, implying that apoE4 can directly modulate
insulin signaling. However, as both apoE4 and LRP1 can bind to
IR, we cannot rule out the possibility that they have competing or
synergistic effects on the regulation of insulin signaling. Further
investigations are necessary to define the role of LRP1 in apoE
isoform-regulated insulin signaling.
In summary, our study not only reveals an age-dependent
deleterious effect of apoE4 that is further accelerated by periph-
eral insulin resistance conditions, but also uncovers an underly-
ing molecular mechanism by which apoE4 retains IR in the
endosomes.We believe that the potentially aggregative behavior
of apoE4 is responsible for several pathogenic effects of apoE4,
including trapping functional receptors in non-productive com-
partments. Gaining a better understanding on the mechanisms
of apoE-regulated insulin signaling should enhance our under-
standing about why APOE4 is a strong risk factor for cognitive
decline and AD and teach us about how we can target apoE in
an isoform-specific manner to improve cerebral insulin signaling
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Meridian Life Science Cat# K74180B, RRID: AB_150544
GSK-3beta (27C10) Rabbit mAb antibody Cell Signaling Technology Cat# 9315, RRID: AB_490890
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Aperio ImageScope Leica Biosystems http://www.leicabiosystems.com/
ImageJ NIH https://imagej.nih.gov/ij/index.html
Odyssey Imaging Systems LI-COR https://www.licor.com/
Prism 7.0 GraphPad Software http://www.graphpad.com/CONTACT FOR REAGENT AND RESOURCE SHARING
Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Dr. Guo-
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EXPERIMENTAL MODEL AND SUBJECT DETAILS
Animals
All animal procedures were approved by the Mayo Clinic Institutional Animal Care and Use Committee (IACUC) and were in accor-
dancewith the National Institutes of Health Guide for the Care andUse of Laboratory Animals. ApoE-targeted replacement (apoE-TR)
mice in which murine Apoe gene locus is replaced with human APOE3 or APOE4 gene were obtained from Taconic. Animals were
housed under controlled conditions of temperature and lighting and given free access to food and water. Male and female apoE-TR
mice at 3, 12 and 22 months of age were used in glucose metabolism and insulin signaling experiments.
In HFD treatment experiments, 8-month-old male and female apoE3- and apoE4-TR mice were kept on a high fat (60% fat,
Research Diets, D12492) or normal fat diet (5.8%, Harlan Laboratories, 7012) for 4 months. The body weight of the mice was eval-
uated everymonth during the experiments. Fasting blood glucose levels were examined using a blood glucosemeter at the end of the
experiment (Nipro Diagnostics).
METHOD DETAILS
In Vivo Brain Insulin Delivery by Reverse Microdialysis
Insulin (100 mIU/min, Sigma) was administrated into the left hippocampus of the 22-month-old apoE-TR mice or HFD-treated apoE-
TR mice via in vivo reverse microdialysis as described (Liu et al., 2015). Mice were anesthetized with 1%–2% isoflurane, and guide
cannula (CMA Microdialysis or Bioanalytical Systems) were surgically implanted into the hippocampus (3.1 mm behind bregma,
2.5 mm lateral to midline, and 1.2 mm below dura at a 12 angle) using a standard stereotaxic frame (Kopf). Mice were allowed to
recover for 24 hr. Microdialysis experiments were performed on conscious, freely moving mice. Mice were fasted overnight before
the experiment. On the day of the experiment, the stylet in the guide cannula was replaced with the microdialysis probe. Probes of
30 kDa molecular weight cutoff membrane (Bioanalytical Systems) were used. The probe was perfused at 2 ml/min with aCSF
(145 mM NaCl, 1.2 mM CaCl2, 3 mM KCl, and 1.0 mM MgCl2) for a 2 hr equilibration period before insulin delivery. HFD-treated
mice were harvested after 1 hr of insulin treatment and the brain lysates were analyzed by western blotting. The 22-month-old
apoE-TR mice were harvested after 4 hr of treatment to examine insulin signaling activation, and the brain lysates were analyzed
by western blotting.
Animals and Brain Tissue Preparation
For tissue preparation, mice were transcardially perfused with saline. Different regions of brain tissues (cortex and hippocampus)
were frozen on dry ice and stored at80C. For biochemical analysis, the brain tissueswere homogenized and lysedwith RIPA buffer
(Thermo Fisher Scientific) containing protease inhibitor cocktail and phosphatase inhibitor (Roche), and centrifuged at 40,000 g for
60 min at 4C. The supernatants were collected as RIPA fractions. The pellets were resuspended in guanidine-HCl (GND, 5 M) and
centrifuged at 40,000 g for 60min at 4C. The supernatants were collected asGND fractions (Liu et al., 2016). All fractions were stored
in 80C until used for western blot and ELISA analysis.
In Vivo Peripheral Insulin Delivery and Tissue Preparation
The apoE-TR mice (22 months of age) with overnight fasting were anesthetized by intraperitoneal administration of Ketamine/
Xylazine cocktail, and insulin (5 U, Sigma) was injected through the inferior vena cava. The hindlimb muscles (gluteus and soleus)
were removed 4min after insulin injection, and were homogenized and lysed in RIPA buffer (Thermo Fisher Scientific) containing pro-
tease inhibitor cocktail and phosphatase inhibitor (Roche). The resulting supernatants were used for western blot analysis.Neuron 96, 115–129.e1–e5, September 27, 2017 e2
Primary Neuron Culture and Treatment Paradigm of ApoE and Insulin
Primary mouse cortical neurons were obtained from 16-18 d embryos of Apoe/ mice. Cultures were grown in neurobasal medium
supplemented with B27 (Thermo Fisher Scientific), 0.5 mM glutamine, 100 U/ml penicillin and 100 g/ml streptomycin. Neurons were
seeded at a density of 106 cells/per well in 6-well plates or 33 104 cells/per well in 96-well plates. At 5 days in vitro (DIV), the cells were
treated with cytosine arabinofuranoside (Ara-C, Sigma) to eliminate glia cells. At DIV10, the cells were treated overnight with 50 nM
recombinant apoE (Fitzgerald) in neurobasal medium supplemented with B27 minus insulin (Thermo Fisher Scientific). Insulin was
administrated for half an hour at a concentration of 100 nM before harvesting the cells for insulin signaling analysis by western
blotting.
ApoE and Insulin Treatment in HuH7 Cells
HuH7 cells were seeded at a density of 0.53 106 cells/per well in 6-well plates and treated overnight with 50 nM recombinant apoE
(Fitzgerald) in serum-free DMEMmedium. Insulin was administrated for 5, 15, 30 or 60 min at a concentration of 100 nM before cells
were harvested for insulin signaling analysis by western blotting.
Purification of Lipidated ApoE from Culture Medium
Immortalized mouse astrocytes derived from apoE3-TR and apoE4-TR mice were cultured as described previously (Morikawa et al.,
2005). Culturemediumwas conditionedwith serum-freemedium for 3648 hr. Conditionedmediumwas concentrated using Amicon
centrifugal filter unit (Millipore), and run through HiTrap Heparin column on an AKTA FPLC system (GE Healthcare). Heparin-bound
apoE was eluted with NaCl gradient from 0 to 1 M in Tris buffer. Cholesterol concentration was detected for each fraction by the
Amplex Red Cholesterol Assay kit (Thermo Fisher). The peak fractions containing apoE that is associated with cholesterol were
concentrated. The concentration and purity of apoE was quantified by apoE ELISA as (Fu et al., 2016).
Measurement of Mitochondrial Respiration and Glycolysis
Mitochondrial respiration and glycolysis were measured by directly detecting oxygen consumption (OCR) and extracellular acidifi-
cation rate (ECAR) respectively using a Seahorse XF96 Extracellular Flux analyzer (Seahorse Bioscience). Cortical neurons form
Apoe/ mice were seeded into Seahorse XF96-well plates at a density of 30,000 cells per well. At DIV8, one day before seahorse
experiment, the cells were treated with 50 nM recombinant or lipidated apoE isoforms for overnight in neurobasal medium supple-
mented with B27 minus insulin. Sensor cartridges were hydrated in XF calibrant and maintained at 37C in air without CO2 one day
before the experiment. The mitochondrial stress test was performed according to the Seahorse Bioscience protocol. In brief, on the
day of the mitochondria stress tests, cells were treated with 100 nM insulin for 30 min and then washed once and incubated with
bicarbonate-free low-buffered assay medium (glucose 10 mM, glutamine 2 mM, sodium pyruvate 1 mM, pH adjusted to 7.4 with
NaOH) for 1 hr at 37C in the absence of CO2 prior to the beginning of the assay. Changes in cellular respiration were assessed
over time after sequential injections of 2 mMoligomycin in port A, 1 mMFCCP in port B and 5 mM rotenone/antimycin A in port C. Three
measurements were performed in each session at 3 min intervals. From themitochondrial assay we determined the following param-
eters: the basal respiration (average OCR of three measurements preceding oligomycin injection), and the maximal respiration
(average OCR of three measurements between FCCP and before rotenone/antimycin A injection).
The glycolysis stress test was performed according to the Seahorse Bioscience protocol. Briefly, on the day of the experiment cells
were washed once and incubated with bicarbonate-free low-buffered glycolysis assay medium (glucose-free, glutamine 2 mM,
pH adjusted to 7.4 with NaOH) for 1 hr at 37C in the absence of CO2 prior to the beginning of the assay. The glycolysis stress
test employed in the present study used sequential injections of glucose (10 mM, port A), oligomycin (2 mM, port B) and 2-deoxyglu-
cose (50 mM, port C). Three measurements were performed in each session at 3 min intervals. From the glycolysis assay we deter-
mined the following parameters: the glycolysis rate (average ECAR of three measurements between glucose and oligomycin
injection), and the glycolytic capacity (average ECAR of three measurements between oligomycin and 2-deoxyglucose injection).
Cell Surface Biotinylation
At DIV10, primary neurons fromApoe/micewere treated overnight with 100 nM recombinant apoEwith or without insulin for 30min
at 37C. Neurons were washed with cold PBS once and then incubated in PBS containing 0.5 mg/mL sulfo-NHS-SS-biotin (Pierce)
for 30 min at 4Cwith shaking. Excess reagent was quenched by rinsing in cold PBS containing 50mM glycine. Cells were lysed with
RIPA containing protease inhibitor cocktail for 20 min at 4C. Cell lysate was collected and centrifuged at 10,0003 g for 10min. After
protein quantification with BCA kit (Pierce), the cell lysates with same amount of protein was incubated with 100 mL of NeutrAvidin
agarose (Pierce) at 4C for 2 hr. Agarose beads were washed three times in PBS contained with protease inhibitor cocktail.
Biotinylated surface proteins and total proteins were analyzed by western blotting.
Truncated apoE preparation
The full-length or C-terminal truncated apoE3 and apoE4were subcloned and inserted into a pcDNA3.1(+) vector betweenHindIII and
XhoI sites. HEK293T cells cultured in DMEM high glucose containing 10% FBS and penicillin/streptomycin were transfected with the
plasmids using polyethylenimine (PEI). Twenty-four hours after the transfection, culture medium was changed to serum-free DMEM
and conditioned for 3648 hr. The conditioned medium was concentrated and run through a HiTrap heparin column on an AKTAe3 Neuron 96, 115–129.e1–e5, September 27, 2017
FPLC system (GE Healthcare). Heparin-bound apoE was eluted with 0 to 1 M gradient of NaCl. The peak fractions containing apoE
were concentrated, and quantified by immunoblot with a monoclonal anti-apoE antibody.
Solid-phase Binding Assay
Recombinant apoE3 or apoE4, astrocyte-secreted lipidated apoE3 or apoE4 particles, C-terminal truncated apoE3 or apoE4, and
recombinant apoJ were coated into 96-well plate (400 ng/well) overnight at 4C. After washing and blocking with ACE blocking buffer
(AbD Serotec) for 3 hr at room temperature, biotinylated human insulin (Eagle Biosciences) or human IR (R&D Systems) at a concen-
tration between 0 to 700 nM (in PBS containing 1% BSA) were added and incubated for 24 hr at 4C. After washing, biotinylated
insulin was detected with poly-avidin-HRP (Fitzgerald Industries) for 1 hr at room temperature. IR was detected by incubating
with biotinylated anti-human IR antibody (R&D Systems) for 2 hr at room temperature, followed by poly-avidin-HRP (Fitzgerald
Industries) for 1 hr at room temperature. After washing, the ELISA assays were developed using Super Slow ELISA TMB (Sigma)
with absorbance read on a Bio-Tek plate reader. To establish the working condition of insulin and IR interaction, recombinant bio-
tinylated human insulin (8 nM) and recombinant IR (at a concentration between 0 to 300 nM) were incubated in 96-well plate at 37C
for 1 hr. To test whether apoE could compete the interaction of insulin and IR, recombinant apoE3 or apoE4 (4, 8, or 16 mg/ml) was
mixed with biotinylated human insulin (8 nM) and recombinant IR (80 nM) and incubated at 37C for 1 hr. The mixed solution was
transferred into Streptavidin Coated plate (R&D Systems) and incubated at 4C for 24 hr. After washing the plate, mouse anti-human
IR antibody (R&DSystems) was added and incubated at room temperature for 2 hr. Plates werewashed and then incubatedwith anti-
mouse IgG-HRP antibody (GE Healthcare) for 2 hr at room temperature. The ELISA assays were developed using Super Slow ELISA
TMB (Sigma) with absorbance read on a Bio-Tek plate reader.
Solution Binding Assay and Co-immunoprecipitation
Recombinant human apoE protein (1 mM, Fitzgerald) and IR protein (400 nM, R&D Systems) were incubated for 1 hr at 37C in 20 ml of
phosphate-buffered saline at neutral pH. The solution complex was immunoprecipitated overnight at 4Cusing the biotin-conjugated
mouse monoclonal apoE antibody (K74180B, Meridian Life Science) or biotin-conjugated rabbit IgG (Thermo Fisher Scientific) as
control. The antibody-bound complexes were isolated by incubation with Avidin-agarose beads (Thermo Fisher Scientific). The pre-
cipitates were then washed three times with PBS and resuspended in SDS sample buffer. The amount of apoE and IR was detected
by western blotting by using the following antibodies: anti-apoE (WUE4, Novus) and anti-IR (Santa Cruz Biotechnology).
Transfection of IR-GFP Plasmids and Confocal Microscopy
SH-SY5Y cells were cultured on 8-well chamber (Ibidi) for 24 hr and then transfected with human IR tagged with GFP (IR-GFP) plas-
mids (Addgene Plasmid #22286) using Lipofectamine 3000 (Thermo Fisher Scientific) according to the manufacturer’s instructions.
Twenty-four hours after transfection, cells were treated overnight with recombinant apoE3 or apoE4 proteins at a concentration of
100 nM. Cells were incubated with Alexa568-labeled human transferrin (Tf) or Lysotracker Red DND99 (Thermo Fisher Scientific) for
1 hr and stimulated with insulin (100 nM) at 30 min before fixation. After fixing with 4% PFA, cells were observed by a confocal laser-
scanning fluorescencemicroscope (Carl Zeiss). The co-localization of proteins was quantified by ImageJ software (National Institutes
of Health), and the Manders’ coefficient was calculated with JACoP (rsbweb.nih.gov/ij/plugins/track/jacop.html).
Endocytosis Assay
IR endocytosis was performed to detect the changes of internalized IR labeled with cleavable biotin as described (Cihil and Swia-
tecka-Urban, 2013; Ehlers, 2000). The Apoe/ primary neurons were incubated in PBS containing 1 mg/mL sulfo-NHS-SS-biotin
(Pierce) for 15 min at 4C with shaking to label the cell surface proteins. The cells were then treated with recombinant apoE
(100 nM) in the presence or absence of insulin (100 nM) at 37C for various times to allow IR trafficking to occur. The remaining surface
biotin was then removed by reducing its disulfide linkage with glutathione cleavage buffer (50 mM glutathione in 75 mM NaCl and
10 mM EDTA containing 1% BSA and 0.075 N NaOH). The internalized (biotinylated) receptors were isolated by precipitation with
streptavidin-conjugated beads, and IRwas detected by western blotting analysis with an anti-IR antibody (Millipore). The internalized
IR was determined by measuring the band intensity at different time points and subtracting the band intensity at time zero.
Recycling Assay
IR recyclingwasmeasured by the loss of internalized IR labeledwith cleavable biotin (Cihil and Swiatecka-Urban, 2013; Ehlers, 2000).
Surface IR of cortical Apoe/ neurons was biotinylated at 4C as above and the cells were then treated with recombinant apoE pro-
teins (100 nM) at 37C for 30 min to allow IR endocytosis to occur. Cells were then cooled at 4C to stop endocytic trafficking and the
cell surface biotin were removed by glutathione cleavage buffer (two times for 15 min each). The cells were then returned to growth
media at 37C for various times to allow the recycling of internalized receptors. The cells were then cooled to 4C and incubated with
glutathione cleavage buffer to ensure complete removal of any newly appeared surface biotin. Residual biotinylated (internalized)
receptors were then isolated by streptavidin precipitation, and IR was detected by western blotting with an anti-IR antibody (Milli-
pore). The internalized IR was determined by measuring the percentage of the band intensity at different time points to the band in-
tensity at time zero. The reduction of intracellular IR provides a measure of receptor recycling.Neuron 96, 115–129.e1–e5, September 27, 2017 e4
IR and ApoE ELISA
Levels of IR and apoE were determined by ELISAs. IR ELISA was performed according to the manufacturer instructions (LifeSpan
BioSciences). For apoE ELISA, WUE4 capture antibody (Novus) and biotin-conjugated mouse monoclonal K74180B detector anti-
body (Meridian Life Science) were used as described (Fu et al., 2016). Recombinant human apoE3 and apoE4 (Fitzgerald) were used
as standard. Colorimetric quantification was performed on a Synergy HT plate reader (BioTek) using horseradish peroxidase (HRP)-
linked streptavidin (Vector) and Super Slow ELISA TMB (Sigma).
Histology and Immunohistochemistry
The hemibrain of apoE-TR mice fixed in 10% formalin was embedded in paraffin wax, sectioned in a coronal plane at 5 micron thick-
ness and mounted on glass slides. The tissue sections were deparaffinized in xylene and rehydrated in a graded series of alcohols.
Antigen retrieval was performed by steaming in Tris-EDTA buffer (Abcam) for 30 min, and endogenous peroxidase activity was
blocked by incubation in 0.03% hydrogen peroxide. Sections were then immunostained with Rab5 antibody (Abcam) by using the
DAKO Autostainer (DAKO North America, Carpinteria, CA) and the DAKO EnVision+HRP system. The stained slides were then de-
hydrated, coverslipped, scanned with the Aperio Slide Scanner (Aperio, Vista, CA), and analyzed with Aperio ImageScope.
Western Blotting and Co-immunoprecipitation
Equal amounts of protein from the homogenized tissue lysates or cell lysates were resolved by SDS-PAGE and transferred to PVDF
membranes. After themembranes were blocked, proteins were detected with primary antibody. Membrane was probed with LI-COR
IRDye secondary antibodies and detected using the Odyssey infrared imaging system (LI-COR). In some experiments, HRP-conju-
gated secondary antibody was visualized by ECL detection system (Pierce) and exposed to film. The following antibodies were used
in this study: anti-phospho-Ser473-Akt (p-Akt, Cell Signaling Technology), anti-Akt (Cell Signaling Technology), anti-phospho-Ser9-
GSK3b (p-GSK3b, Cell Signaling Technology), anti-GSK3b (Cell Signaling Technology), anti-phospho-Tyr1345 IR (p-IR, Cell
Signaling Technology), anti-IR (SantaCruz Biotechnology), anti-apoE antibodies (Meridian Life Science), anti-LRP1 antibody
[in-house, (Bu et al., 1995)], anti-NMDAR(NR2B) antibody (Millipore), anti-AMPAR(GluR2) antibody (Millipore), anti-Na-K-ATPase
antibody(Abcam), and anti-b-actin (Sigma) antibodies.
For IR immunoprecipitation, the brain lysates were pre-cleared using Protein A-agarose beads (ThermoFisher Scientific) for 30 min
at 4C and immunoprecipitated overnight at 4C using anti-IR antibody (Santa Cruz Biotechnology) and Protein A-agarose beads.
The precipitates were then washed three times with PBS and resuspended in SDS sample buffer for western blotting. ApoE immu-
noprecipitation was performed by using the biotin-conjugated mouse monoclonal apoE antibody (K74180B, Meridian Life Science)
and Avidin-agarose beads (ThermoFisher Scientific).
Statistical Analysis
Comparisons between two groups were performed with Student’s t tests, and those among more than two groups were performed
with ANOVA. A p value of < 0.05 was considered statistically significant.e5 Neuron 96, 115–129.e1–e5, September 27, 2017
